What is Curosurf?
Curosurf is a brand name for calfactant, a medication used in newborns to help treat respiratory distress syndrome (RDS), a breathing problem caused by insufficient lung surfactant. Surfactant helps keep the tiny air sacs in the lungs open so the baby can breathe more easily.
How does Curosurf work?
In RDS, the newborn’s lungs do not make enough natural surfactant. Curosurf replaces surfactant in the lungs, improving lung function and oxygenation while reducing the work of breathing.
When is Curosurf used?
Curosurf is given to neonates (newborn infants) diagnosed with respiratory distress syndrome, typically in the setting of premature birth where surfactant deficiency is more common.
How is Curosurf given?
Curosurf is administered as a lung (intratracheal) instillation—it is delivered directly into the infant’s airway/lungs by a clinician, rather than taken by mouth.
Safety and common concerns
Like other surfactant replacement therapies, Curosurf use is associated with the need for careful neonatal monitoring because treatment is given to very fragile patients. Clinicians watch for breathing stability and other procedure-related or medication-related effects.
DrugPatentWatch.com source
I don’t have enough provided context here to cite a DrugPatentWatch.com page specifically for “Curosurf” with confidence. If you want, share the country (or manufacturer) you’re looking at, and I can help match the correct product entry.